Launching a Precision Medicine Program: Real-World Solutions to Practical Challenges

Mar 28, 2017
Track 2
11:20 AM - 12:10 PM

Healthcare systems are implementing precision medicine programs. They view their precision medicine programs as critical to providing the best patient care as well as to remaining competitive in the market. However, they face practical challenges, including empowering physicians with education on the value of molecular testing; access to high-quality, patient-specific interpretation of molecular diagnostic test results; and improving patient access to drugs, including through clinical trials.

This panel will discuss:

  • What are some of the biggest barriers to the launch and scaling of a precision medicine program, for both the pathologist and the oncologist?
  • What are some of the solutions to these challenges?
  • How are decisions made on the type of testing to offer?
  • What is the role of the molecular tumor board?
  • Why are clinical trials critical to the success of the program?
  • How is your institution/organization addressing the need for providing access to clinical trials?
  • What are some of the challenges around reimbursement and how are you addressing them?
  • How do you see the role of the patient evolving and how are you addressing these changes?


Anna B. Berry, MD, Scientific Director of Personalized Medicine, Swedish Cancer Institute & Medical Director of Molecular Diagnostics, CellNetix Pathology and Laboratories

Timothy L. Cannon, MD, Medical Oncologist and Clinical Director, Molecular Tumor Board and Personalized Medicine Initiative, Inova Schar Cancer Institute

Brad Perkins, MD, Chief Medical Officer, Human Longevity, Inc.

MODERATOR: Jennifer Levin Carter, MD, MPH, Chief Medical Officer and Founder, N-of-One